• Forum
  • Aktiemarkeder
    • MarkederRealtidskurser, indekser og markedsudvikling
    • BørskalenderKommende resultater, noteringer og virksomhedsbegivenheder
    • UdbyttekalenderKommende og tidligere udbytter
  • Selskaber
    • SelskaberGennemse og filtrer den fulde liste over børsnoterede selskaber
    • OpdagInspiration til din næste investering
    • BørsnoteringerNye noteringer og kommende børsintroduktioner
    • Invitationer til generalforsamlingerDatoer for generalforsamlinger og aktionærinformation
  • Aktieanalyse
    • ResearchEkspertaktieanalyse og anbefalinger
    • ArtiklerNyheder, indsigter og markedskommentarer
    • inderesTVVideocenter for aktieanalyse, forskning og ekspertkommentarer
    • TransskriptionerFuldstændige udskrifter af resultatopkald og investormøder
    • AktieoversigtSammenlign nøgletal og udvikling på tværs af flere aktier
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find os på de sociale medier
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Vores team
  • Karriere
  • Inderes som en investering
  • Tjenester for børsnoterede virksomheder
Vores platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer

Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.

Photocure ASA - Share option grant

PHOSelskabsmeddelelse29.07.2026, 21.48
Oslo, Norway, 29 July 2026 - Photocure ASA (the "Company") (OSE: PHO) has
granted share options to employees.

A total of 265,000 share options, equal to 0.98% of total shares issued in the
Company, were granted to the executive leadership team at an exercise price at
NOK 63,93 per share (the "ELT Options"). The exercise price is equal to the
weighted average share price 30 trading days before day of grant with an
additional premium of 10% on top of the calculated average price.

The ELT Options are granted in accordance with Photocure's long term incentive
program and the Company's guidelines for remuneration of senior executives (the
"Guidelines"), as approved by Photocure's annual general meeting held 26 June
2026. The share option program and properties of the options are further
described in the Guidelines.

The following ELT Options were granted to primary insiders:

·           Daniel Schneider, President and Chief Executive Officer, 100,000
options

·           Geoffrey Coy, Vice President and General Manager North America,
40,000 options

·           Jane Healy, Vice President and General Manager Europe, 50,000
options

·           Anders Neijber, Chief Medical Officer, Global Medical Affairs and
Clinical Development and R&D, 40,000 options

·           Anja Gossens-Von Der Heidt, Head of Global Human Resources, 35,000
options

Primary insider notifications pursuant to the market abuse regulation article 19
are attached.

For further information, please contact:

Priyam Shah

Vice President Investor Relations

Tel : +17176815072

Email: priyam.shah@photocure.com

About Photocure ASA

Photocure is a commercial diagnostic company with global reach, committed to
driving progress in uro-oncology precision diagnostics, delivering meaningful
advances for patients with urological cancers. Our unique core technology has
led to better health outcomes for patients worldwide. The company aims to
provide an array of transformative solutions that help physicians with timely
diagnostic information, to inform more personalized decisions on how best to
manage each individual patient. Photocure is headquartered in Oslo, Norway and
listed on the Oslo Stock Exchange (OSE: PHO). For more information, please visit
www.photocure.com/news

This information is subject to the disclosure requirements pursuant to the
market abuse regulation article 19 and 5-12 of the Norwegian Securities Trading
Act.
he\
market abuse regulation article 19 and 5-12 of the Norwegian Securities Trading\
Act.\